Evidence map›Paper›PMID 35100079›Full record

ArticleCell cycle (Georgetown, Tex.)

miR-30b-5p inhibits osteoblast differentiation through targeting BCL6.

Yan Luo, Feng Zhou, Xiaochun Wu, Yi Li, Bin Ye

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. MiR-30 Family: A Novel Avenue for Treating Bone and Joint Diseases?International journal of medical sciences · 2023
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan LuoDepartment of General Practice, Wuhan Puren Hospital, Wuhan, Hubei, China.
Feng ZhouDepartment of Endocrinology, Wuhan Puren Hospital, Wuhan, Hubei, China.
Xiaochun WuDepartment of Orthopaedics, Wuhan Huangpi People Hospital, Wuhan, Hubei, China.
Yi LiDepartment of General Practice, Wuhan Puren Hospital, Wuhan, Hubei, China.
Bin YeDepartment of Orthopaedics, Wuhan No. 9 Hospital, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human bone marrow mesenchymal stem cells (hBMSCs) are attractive candidates for new therapies to improve bone regeneration and repair. This study was to identify the function of the miR-30b-5p/BCL6 axis in osteogenic differentiation of hBMSCs. Realtime-quantitative PCR (RT-qPCR) and Western blotting were used to measure the relative expression of ALP, OCN, RUNX2, miR-30b-5p, and BCL6 during osteogenic differentiation of hBMSCs. The relationship between miR-30b-5p and BCL6 in hBMSCs was identified using dual-luciferase reporter system and RNA pull-down assay. Alizarin red S staining (ARS) was used to detect the calcium nodules in hBMSCs. We found that the expression of miR-30b-5p was downregulated, whereas that of BCL6 was upregulated during osteogenic differentiation of hBMSCs. Downregulating miR-30b-5p enhanced the expression of OCN, RUNX2, and ALP, and promoted calcium deposition. Conversely, transfection with si-BCL6 had the opposite effect that it inhibited osteogenic differentiation. However, the inhibitory effect of si-BCL6 was abrogated by miR-30b-5p inhibitor. miR-30b-5p inhibits the osteogenic differentiation of hBMSCs by targeting BCL6.

Indexed as

Cell DifferentiationMicroRNAsOsteogenesisProto-Oncogene Proteins c-bcl-6CalciumCells, CulturedCore Binding Factor Alpha 1 SubunitHumansOsteoblastsBCL6 protein, humanCalciumCore Binding Factor Alpha 1 SubunitMicroRNAsMIRN30a microRNA, humanProto-Oncogene Proteins c-bcl-6BCL6human mesenchymal stem cellmiR-30b-5pmiRNAosteogenic differentiation

Identifiers

PMID35100079
PMCPMC8942429

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.